American Regent vs. Xiromed: Consent Judgment Resolves Trace Elements Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | American Regent, Inc. v. Xiromed, LLC |
| Case Number | 2:25-cv-00723 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Jan 2025 – Jun 2025 131 days |
| Outcome | Plaintiff Win – Consent Judgment & Permanent Injunction |
| Patents at Issue | |
| Accused Products | Xiromed’s proposed generic Tralement® (ANDA No. 219728) |
Case Overview
The Parties
⚖️ Plaintiff
U.S.-based specialty pharmaceutical company, subsidiary of Daiichi Sankyo, known for injectable drug portfolio including Tralement® (trace elements injection 4*, USP).
🛡️ Defendant
Generic pharmaceutical manufacturer that filed ANDA No. 219728 seeking FDA approval to market a generic version of Tralement®.
The Patents at Issue
Five U.S. patents were asserted, all protecting the formulation, composition, and use of the trace elements injection product:
- • US11,786,548 (App. No. 17/365,695)
- • US11,975,022 (App. No. 18/482,612)
- • US11,998,565 (App. No. 18/124,391)
- • US12,150,956 (App. No. 18/653,608)
- • US12,150,957 (App. No. 18/672,876)
Developing a generic pharmaceutical?
Check if your product might infringe these or related patents.
The Verdict & Legal Analysis
Outcome: Consent Judgment and Permanent Injunction
The case concluded via a consent judgment entered on May 23, 2025, with a **permanent injunction** prohibiting XIROMED from making, using, selling, offering to sell, importing or distributing their generic Tralement® in the United States, unless authorized by ARI. No damages amount was disclosed, replaced by confidential “good cause and valuable consideration.” All claims were dismissed without prejudice.
Legal Significance
The underlying cause was a patent infringement action under the Hatch-Waxman Act, triggered by XIROMED’s ANDA filing. The swift resolution highlights the enforceability of tightly clustered pharmaceutical patent portfolios. ARI’s five-patent assertion, filed across 2021–2024, reflects a robust evergreening strategy for Tralement®.
Filing a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims for complex formulations.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis for Pharmaceutical Formulations
This case highlights critical IP risks in generic drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related Tralement® patents in this technology space
- See which companies are most active in parenteral nutrition IP
- Understand ANDA litigation claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your formulation or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Parenteral nutrition formulations
5 Asserted Patents
In Tralement® portfolio
ANDA Litigation
Swift resolution in 131 days
✅ Key Takeaways
For Patent Attorneys & Litigators
Dense, multi-patent portfolios maximize settlement leverage in Hatch-Waxman cases.
Search related case law →Consent judgments with permanent injunctions are effective for prompt resolution without trial risk.
Explore precedents →For R&D Teams
Prioritize early FTO clearance for generic formulations, covering continuation and CIP families.
Start FTO analysis for my product →Pharmaceutical lifecycle management benefits from layered patent protection post-approval.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.